作者
Nor Rahimah Aini, Norhayati Mohd Noor, Mohd Khairi Md Daud, Sarah K Wise, Baharudin Abdullah
发表日期
2021/8
来源
Clinical and translational allergy
卷号
11
期号
6
页码范围
e12055
简介
Background
Intralymphatic immunotherapy (ILIT) is a potential treatment option for allergic rhinitis (AR). We aimed to determine the efficacy (primary outcomes) and safety (secondary outcomes) of ILIT in treating patients with AR.
Methods
An electronic literature search was performed using MEDLINE and Cochrane Central Register of Controlled Trials CENTRAL (from their inception to December 2020). A random‐effects model was used to estimate the pooled prevalence with 95% confidence intervals. This study is registered with PROSPERO (CRD42019126271).
Results
We retrieved a total of 285 articles, of which 11 satisfied our inclusion criteria. There were 452 participants with age ranged from 15 to 58 years old. Intralymphatic immunotherapy was given in three doses with intervals of four weeks between doses in 10 trials. One trial gave three and six doses with an interval of two weeks. Both primary and …
学术搜索中的文章
NR Aini, N Mohd Noor, MK Md Daud, SK Wise… - Clinical and translational allergy, 2021